At the time of writing, Mersana Therapeutics Inc [MRSN] stock is trading at $0.41, up 4.15%. An important factor to consider is whether the stock is rising or falling in short-term value. The MRSN shares have gain 16.69% over the last week, with a monthly amount glided 27.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On March 19, 2024, upgrade upgraded it’s rating to Neutral but maintained its price target of $5 on the stock. Wedbush upgraded its rating to a Outperform and increased its price target to $7 on February 29, 2024. Guggenheim upgraded its rating to a Buy but $7 remained the price target by the analyst firm on February 29, 2024. BTIG Research upgraded its rating to Buy for this stock on February 29, 2024, but kept the price target unchanged to $6. In a note dated December 04, 2023, Citigroup upgraded an Buy rating on this stock and boosted its target price from $1 to $5.
For the past year, the stock price of Mersana Therapeutics Inc fluctuated between $0.26 and $2.83. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Mersana Therapeutics Inc [NASDAQ: MRSN] shares were valued at $0.41 at the most recent close of the market. An investor can expect a potential return of 631.71% based on the average MRSN price forecast.
Analyzing the MRSN fundamentals
According to Mersana Therapeutics Inc [NASDAQ:MRSN], the company’s sales were 34.01M for trailing twelve months, which represents an -70.21% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -2.26%, Pretax Profit Margin comes in at -2.16%, and Net Profit Margin reading is -2.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is 9.58 and Total Capital is -1.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Mersana Therapeutics Inc [NASDAQ:MRSN] has a current ratio of 1.83. On the other hand, the Quick Ratio is 1.83, and the Cash Ratio is 1.76. Considering the valuation of this stock, the price to sales ratio is 1.49.
Transactions by insiders
Recent insider trading involved Mandelia Ashish, VP, Chief Accounting Officer, that happened on Jan 16 ’25 when 3554.0 shares were sold. Director, Protopapas Anna completed a deal on Jan 16 ’25 to sell 8637.0 shares. Meanwhile, SVP, Chief Sci.&Tech. Officer Lowinger Timothy B sold 8048.0 shares on Jan 16 ’25.
